{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:33:08Z","timestamp":1777419188189,"version":"3.51.4"},"reference-count":24,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2008,8,26]],"date-time":"2008-08-26T00:00:00Z","timestamp":1219708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2008,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To report a case of probable propylene glycol (PG) toxicity in a patient receiving continuous infusion of pentobarbital for refractory status epilepticus.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Summary:<\/jats:title>\n                    <jats:p>A 59-yoar-old woman with a declining mental status was admitted to the intensive care unit for management of status epilepticus. After failing to achieve the therapeutic endpoint of electroencephalogram burst suppression with a continuous infusion of propofol, the sedative regimen was changed to continuous infusion of pentobarbital. The patient received a loading dose of 450 mg (5 mg\/kg), and the maintenance infusion was titrated to a dose of 10 mg\/kg\/h to achieve burst suppression. Twelve hours after the pentobarbital infusion was started, the patient developed an anion gap metabolic acidosis, elevated serum lactate level, hyperosmolality, and increased osmolal gap. The pentobarbital infusion was discontinued, and the patient's acidosis and hyperosmolality resolved.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>Pentobarbital contains 40% v\/v of PG, which was thought to be a potential source of the patient's metabolic derangements. Reports of toxicity with drugs containing PG. particularly intravenous lorazepam, have been well described in the literature. What we describe, however, is one of few reports involving intravenous pentobarbital. The Naranjo probability scale supports a probable drug-related adverse event in our patient.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>PG toxicity is a potential complication associated with intravenouspentobarbital. Practitioners should be aware of the PG content of pentobarbital and should be familiar with the signs and symptoms associated with PG toxicity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1l186","type":"journal-article","created":{"date-parts":[[2008,8,12]],"date-time":"2008-08-12T23:39:50Z","timestamp":1218584390000},"page":"1502-1506","source":"Crossref","is-referenced-by-count":37,"title":["Propylene Glycol-Induced Lactic Acidosis in a Patient Receiving Continuous Infusion Pentobarbital"],"prefix":"10.1177","volume":"42","author":[{"given":"Melissa A","family":"Miller","sequence":"first","affiliation":[{"name":"Critical Care, Department of Pharmacy, University of Massachusetts Memorial Medical Center, Worcester, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison","family":"Forni","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Massachusetts Memorial Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dinesh","family":"Yogaratnam","sequence":"additional","affiliation":[{"name":"Critical Care, Department of Pharmacy, University of Massachusetts Memorial Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2008,8,26]]},"reference":[{"key":"bibr1-aph.1L186","volume-title":"POISINDEX System","author":"Propylene glycol"},{"key":"bibr2-aph.1L186","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000134831.40466.39"},{"key":"bibr3-aph.1L186","doi-asserted-by":"publisher","DOI":"10.1378\/chest.128.3.1674"},{"key":"bibr4-aph.1L186","doi-asserted-by":"publisher","DOI":"10.4037\/ajcc1999.8.1.499"},{"key":"bibr5-aph.1L186","first-page":"274","volume":"13","author":"D'Ambrosio JA","year":"1993","journal-title":"Pharmacotherapy"},{"key":"bibr6-aph.1L186","doi-asserted-by":"publisher","DOI":"10.1592\/phco.21.13.1140.34611"},{"key":"bibr7-aph.1L186","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199804023381407"},{"key":"bibr8-aph.1L186","doi-asserted-by":"publisher","DOI":"10.1378\/chest.126.2.582"},{"key":"bibr9-aph.1L186","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2002.28501.x"},{"key":"bibr10-aph.1L186","doi-asserted-by":"publisher","DOI":"10.1385\/NCC:4:1:035"},{"key":"bibr11-aph.1L186","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1992.tb04635.x"},{"key":"bibr12-aph.1L186","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"bibr13-aph.1L186","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(97)90577-1"},{"key":"bibr14-aph.1L186","first-page":"27810","volume":"47","author":"Food and Drug Administration","year":"1982","journal-title":"Fed Regist"},{"key":"bibr15-aph.1L186","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(70)80253-0"},{"key":"bibr16-aph.1L186","first-page":"114","volume":"62","author":"Christopher MM","year":"1990","journal-title":"Lab Invest"},{"key":"bibr17-aph.1L186","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1G083"},{"key":"bibr18-aph.1L186","doi-asserted-by":"publisher","DOI":"10.1016\/0041-008X(72)90032-4"},{"key":"bibr19-aph.1L186","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-198709000-00001"},{"key":"bibr20-aph.1L186","volume-title":"Nembutal (pentobarbital sodium)","author":"Product information.","year":"2005"},{"key":"bibr21-aph.1L186","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1A321"},{"key":"bibr22-aph.1L186","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-003-1905-x"},{"key":"bibr23-aph.1L186","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2005.08.024"},{"key":"bibr24-aph.1L186","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.35.991"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1L186","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1L186","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:09:49Z","timestamp":1777374589000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1L186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,26]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["10.1345\/aph.1L186"],"URL":"https:\/\/doi.org\/10.1345\/aph.1l186","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,26]]}}}